Ring finger 20/ring finger 40/WW domain‑containing adaptor with coiled‑coil complex interacts with p53 to regulate gene transcription in DNA damage response

Meng,Danni; Guo,Kun; Zhang,Die; Zhao,Cheng; Sun,Chuanwen; Zhang,Feng

doi:10.3892/ol.2021.12697

Ring finger 20/ring finger 40/WW domain‑containing adaptor with coiled‑coil complex interacts with p53 to regulate gene transcription in DNA damage response

Authors:
- Danni Meng
- Kun Guo
- Die Zhang
- Cheng Zhao
- Chuanwen Sun
- Feng Zhang
View Affiliations

Affiliations: College of Life Sciences, Shanghai Normal University, Shanghai 200234, P.R. China
Published online on: April 1, 2021 https://doi.org/10.3892/ol.2021.12697
Article Number: 436
Copyright: © Meng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

p53 is one of the most important tumor suppressor genes, and its primary function is to act as a transcriptional activator to control cell cycle arrest, DNA repair and cellular metabolism by recognizing and binding to specific DNA sequences. Defects in the ring finger (RNF)20/RNF40/WW domain‑containing adaptor with coiled‑coil (WAC) complex, one of the histone H2B ubiquitination E3 ligases, have been reported to be a key factor in oncogenesis, cancer cell migration and invasion. Histone H2B mono‑ubiquitination has been demonstrated to be essential for maintaining the functionality of the p53 tumor suppressor protein. The aim of the present study was to identify any sites in the p53 DNA‑binding domain (DBD) specific to the RNF20/RNF40/WAC complex that may be involved in the gene regulation in DNA damage response. The results demonstrated that p53 and the RNF20/RNF40/WAC complex interacted with each other, and the coiled‑coil regions in RNF20, RNF40 and WAC were identified to directly interact with p53. The R282 site in the p53 DBD, one of the frequent missense mutations associated with p53 mutation‑dependent cancer, was demonstrated to be the key binding site for the RNF20/RNF40/WAC complex. Furthermore, knockout of RNF20/RNF40 suppressed the expression levels of p53 and its target genes in HCT116 cells compared with those in wild‑type HCT116 cells. Consistent with these results, the R282W mutation in p53 inhibited the expression levels of p53 and its downstream genes by inactivating the interaction between p53 and RNF20/RNF40 compared with those in wild‑type HCT116 cells. In conclusion, the results of the present study revealed the molecular mechanism of the interaction between the RNF20/RNF40/WAC complex and p53, and demonstrated that these proteins regulated gene transcription in the DNA damage response.

View Figures

View References

1	Bieging KT, Mello SS and Attardi LD: Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 14:359–370. 2014. View Article : Google Scholar : PubMed/NCBI
2	Joerger AC and Fersht AR: Structural biology of the tumor suppressor p53. Annu Rev Biochem. 77:557–582. 2008. View Article : Google Scholar : PubMed/NCBI
3	Joerger AC and Fersht AR: Structural biology of the tumor suppressor p53 and cancer-associated mutants. Adv Cancer Res. 97:1–23. 2007. View Article : Google Scholar : PubMed/NCBI
4	Ozaki T and Nakagawara A: Role of p53 in Cell Death and Human Cancers. Cancers (Basel). 3:994–1013. 2011. View Article : Google Scholar : PubMed/NCBI
5	Joerger AC and Fersht AR: Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene. 26:2226–2242. 2007. View Article : Google Scholar : PubMed/NCBI
6	Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
7	Allen MA, Andrysik Z, Dengler VL, Mellert HS, Guarnieri A, Freeman JA, Sullivan KD, Galbraith MD, Luo X, Kraus WL, et al: Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. eLife. 3:e022002014. View Article : Google Scholar : PubMed/NCBI
8	Dai C and Gu W: p53 post-translational modification: Deregulated in tumorigenesis. Trends Mol Med. 16:528–536. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bernard M, Yang B, Migneault F, Turgeon J, Dieudé M, Olivier MA, Cardin GB, El-Diwany M, Underwood K, Rodier F, et al: Autophagy drives fibroblast senescence through MTORC2 regulation. Autophagy. 16:2004–2016. 2020. View Article : Google Scholar : PubMed/NCBI
10	Ho CJ, Lin RW, Zhu WH, Wen TK, Hu CJ, Lee YL, Hung TI and Wang C: Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress. Cell Death Discov. 5:1312019. View Article : Google Scholar : PubMed/NCBI
11	Follis AV, Llambi F, Ou L, Baran K, Green DR and Kriwacki RW: The DNA-binding domain mediates both nuclear and cytosolic functions of p53. Nat Struct Mol Biol. 21:535–543. 2014. View Article : Google Scholar : PubMed/NCBI
12	Mrakovcic M and Frohlich LF: p53-mediated molecular control of autophagy in tumor cells. Biomolecules. 8:142018. View Article : Google Scholar
13	Clapier CR and Cairns BR: The biology of chromatin remodeling complexes. Annu Rev Biochem. 78:273–304. 2009. View Article : Google Scholar : PubMed/NCBI
14	Cole AJ, Clifton-Bligh R and Marsh DJ: Histone H2B monoubiquitination: Roles to play in human malignancy. Endocr Relat Cancer. 22:T19–T33. 2015. View Article : Google Scholar : PubMed/NCBI
15	Chandrasekharan MB, Huang F and Sun ZW: Histone H2B ubiquitination and beyond: Regulation of nucleosome stability, chromatin dynamics and the trans-histone H3 methylation. Epigenetics. 5:460–468. 2010. View Article : Google Scholar : PubMed/NCBI
16	Hammond-Martel I, Yu H and Affar B: Roles of ubiquitin signaling in transcription regulation. Cell Signal. 24:410–421. 2012. View Article : Google Scholar : PubMed/NCBI
17	Buetow L and Huang DT: Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat Rev Mol Cell Biol. 17:626–642. 2016. View Article : Google Scholar : PubMed/NCBI
18	Shiloh Y, Shema E, Moyal L and Oren M: RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response. FEBS Lett. 585:2795–2802. 2011. View Article : Google Scholar : PubMed/NCBI
19	Zhang K, Wang J, Tong TR, Wu X, Nelson R, Yuan YC, Reno T, Liu Z, Yun X, Kim JY, et al: Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. Int J Cancer. 141:766–777. 2017. View Article : Google Scholar : PubMed/NCBI
20	Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, et al: The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev. 22:2664–2676. 2008. View Article : Google Scholar : PubMed/NCBI
21	Zhang F and Yu X: WAC, a functional partner of RNF20/40, regulates histone H2B ubiquitination and gene transcription. Mol Cell. 41:384–397. 2011. View Article : Google Scholar : PubMed/NCBI
22	Johnsen SA: The enigmatic role of H2Bub1 in cancer. FEBS Lett. 586:1592–1601. 2012. View Article : Google Scholar : PubMed/NCBI
23	Sethi G, Shanmugam MK, Arfuso F and Kumar AP: Role of RNF20 in cancer development and progression - a comprehensive review. Biosci Rep. 38:BSR201712872018. View Article : Google Scholar : PubMed/NCBI
24	Chernikova SB, Razorenova OV, Higgins JP, Sishc BJ, Nicolau M, Dorth JA, Chernikova DA, Kwok S, Brooks JD, Bailey SM, et al: Deficiency in mammalian histone H2B ubiquitin ligase Bre1 (Rnf20/Rnf40) leads to replication stress and chromosomal instability. Cancer Res. 72:2111–2119. 2012. View Article : Google Scholar : PubMed/NCBI
25	Lee JH, Jeon YG, Lee KH, Lee HW, Park J, Jang H, Kang M, Lee HS, Cho HJ, Nam DH, et al: RNF20 Suppresses Tumorigenesis by Inhibiting the SREBP1c-PTTG1 Axis in Kidney Cancer. Mol Cell Biol. 37:e00265–17. 2017. View Article : Google Scholar : PubMed/NCBI
26	Tarcic O, Granit RZ, Pateras IS, Masury H, Maly B, Zwang Y, Yarden Y, Gorgoulis VG, Pikarsky E, Ben-Porath I, et al: RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer. Cell Death Differ. 24:694–704. 2017. View Article : Google Scholar : PubMed/NCBI
27	Wu C, Cui Y, Liu X, Zhang F, Lu LY and Yu X: The RNF20/40 complex regulates p53-dependent gene transcription and mRNA splicing. J Mol Cell Biol. 12:113–124. 2020. View Article : Google Scholar : PubMed/NCBI
28	Tzin V, Rogachev I, Meir S, Moyal Ben Zvi M, Masci T, Vainstein A, Aharoni A and Galili G: Tomato fruits expressing a bacterial feedback-insensitive 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase of the shikimate pathway possess enhanced levels of multiple specialized metabolites and upgraded aroma. J Exp Bot. 64:4441–4452. 2013. View Article : Google Scholar : PubMed/NCBI
29	Kitzman JO, Starita LM, Lo RS, Fields S and Shendure J: Massively parallel single-amino-acid mutagenesis. Nat Methods. 12:203–206, 4 p following 206. 2015. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Stiewe T and Haran TE: How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resist Updat. 38:27–43. 2018. View Article : Google Scholar : PubMed/NCBI
32	Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, et al: Corrigendum: The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev. 31:19262017. View Article : Google Scholar : PubMed/NCBI
33	Hwang WW, Venkatasubrahmanyam S, Ianculescu AG, Tong A, Boone C and Madhani HD: A conserved RING finger protein required for histone H2B monoubiquitination and cell size control. Mol Cell. 11:261–266. 2003. View Article : Google Scholar : PubMed/NCBI
34	Nakamura K, Kato A, Kobayashi J, Yanagihara H, Sakamoto S, Oliveira DV, Shimada M, Tauchi H, Suzuki H, Tashiro S, et al: Regulation of homologous recombination by RNF20-dependent H2B ubiquitination. Mol Cell. 41:515–528. 2011. View Article : Google Scholar : PubMed/NCBI
35	Kao CF, Hillyer C, Tsukuda T, Henry K, Berger S and Osley MA: Rad6 plays a role in transcriptional activation through ubiquitylation of histone H2B. Genes Dev. 18:184–195. 2004. View Article : Google Scholar : PubMed/NCBI
36	Tang Q, Su Z, Gu W and Rustgi AK: Mutant p53 on the path to metastasis. Trends Cancer. 6:62–73. 2020. View Article : Google Scholar : PubMed/NCBI
37	Vousden KH and Prives C: Blinded by the Light: The growing complexity of p53. Cell. 137:413–431. 2009. View Article : Google Scholar : PubMed/NCBI
38	Li H, Zhang J, Tong JHM, Chan AWH, Yu J, Kang W and To KF: Targeting the oncogenic p53 mutants in colorectal cancer and other solid tumors. Int J Mol Sci. 20:59992019. View Article : Google Scholar
39	Hanel W, Marchenko N, Xu S, Yu SX, Weng W and Moll U: Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 20:898–909. 2013. View Article : Google Scholar : PubMed/NCBI
40	Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science. 265:346–355. 1994. View Article : Google Scholar : PubMed/NCBI
41	Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
42	Kumar P and Wolberger C: Structure of the yeast Bre1 RING domain. Proteins. 83:1185–1190. 2015. View Article : Google Scholar : PubMed/NCBI
43	Shanmugam MK, Arfuso F, Arumugam S, Chinnathambi A, Jinsong B, Warrier S, Wang LZ, Kumar AP, Ahn KS, Sethi G, et al: Role of novel histone modifications in cancer. Oncotarget. 9:11414–11426. 2017. View Article : Google Scholar : PubMed/NCBI
44	Menendez D, Nguyen TA, Freudenberg JM, Mathew VJ, Anderson CW, Jothi R and Resnick MA: Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res. 41:7286–7301. 2013. View Article : Google Scholar : PubMed/NCBI
45	Stein Y, Rotter V and Aloni-Grinstein R: Gain-of-function mutant p53: All the roads lead to tumorigenesis. Int J Mol Sci. 20:61972019. View Article : Google Scholar
46	Zhang Y, Coillie SV, Fang JY and Xu J: Gain of function of mutant p53: R282W on the peak? Oncogenesis. 5:e1962016. View Article : Google Scholar : PubMed/NCBI
47	Xu J, Wang J, Hu Y, Qian J, Xu B, Chen H, Zou W and Fang JY: Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity. Cell Death Dis. 5:e11082014. View Article : Google Scholar : PubMed/NCBI
48	Calhoun S and Daggett V: Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain. Biochemistry. 50:5345–5353. 2011. View Article : Google Scholar : PubMed/NCBI
49	Deyoung MP and Ellisen LW: p63 and p73 in human cancer: Defining the network. Oncogene. 26:5169–5183. 2007. View Article : Google Scholar : PubMed/NCBI
50	Ali A, Shah AS and Ahmad A: Gain-of-function of mutant p53: Mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells. Cancer Lett. 354:87–96. 2014. View Article : Google Scholar : PubMed/NCBI
51	Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ, et al: Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene. 32:2992–3000. 2013. View Article : Google Scholar : PubMed/NCBI
52	Xu J, Qian J, Hu Y, Wang J, Zhou X, Chen H and Fang JY: Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations. Sci Rep. 4:42232014. View Article : Google Scholar : PubMed/NCBI
53	Zhang Y and Hunter T: Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. 134:1013–1023. 2014. View Article : Google Scholar : PubMed/NCBI
54	Tarcic O, Pateras IS, Cooks T, Shema E, Kanterman J, Ashkenazi H, Boocholez H, Hubert A, Rotkopf R, Baniyash M, et al: RNF20 Links histone H2B ubiquitylation with inflammation and inflammation-associated cancer. Cell Rep. 14:1462–1476. 2016. View Article : Google Scholar : PubMed/NCBI
55	Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, MacDuffie E, Song M, Hirsch MS, Lester J, Parkash V, et al: Early loss of histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res. 79:760–772. 2019. View Article : Google Scholar : PubMed/NCBI
56	Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun S and Pang D: Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol. 137:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
57	Minsky N, Shema E, Field Y, Schuster M, Segal E and Oren M: Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat Cell Biol. 10:483–488. 2008. View Article : Google Scholar : PubMed/NCBI
58	Prenzel T, Begus-Nahrmann Y, Kramer F, Hennion M, Hsu C, Gorsler T, Hintermair C, Eick D, Kremmer E, Simons M, et al: Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res. 71:5739–5753. 2011. View Article : Google Scholar : PubMed/NCBI
59	Mimnaugh EG, Chen HY, Davie JR, Celis JE and Neckers L: Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: Effects on replication, transcription, translation, and the cellular stress response. Biochemistry. 36:14418–14429. 1997. View Article : Google Scholar : PubMed/NCBI
60	Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK and Myers JN: TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res. 18:290–300. 2012. View Article : Google Scholar : PubMed/NCBI
61	Okaichi K, Ide-Kanematsu M, Izumi N, Morita N, Okumura Y and Ihara M: Variations in sensitivity to ionizing radiation in relation to p53 mutation point. Anticancer Res. 28((5A)): 2687–2690. 2008.PubMed/NCBI